The Company’s advanced clinical stage portfolio and robust and risk-diversified pipeline comprises anti-infective compounds that have been derived from NovaBiotics’ proprietary rational drug design peptide platform (Novexatin, Novamycin, Novarifyn, Luminaderm) and a ”mini biologic” aminothiol antibacterial-mucolytic compound (Lynovex).
NovaBiotics’ experienced board and management team remain focused on high-value opportunities and the delivery of commercial success from the Company’s solid technology base.
The Company has a strong IP portfolio with multiple patent families granted and pending, protecting NovaBiotics’ technology worldwide. All of the NovaBiotics’ IP is wholly owned by the Company.
To find out more about investment opportunities, contact us.
Using a platform technology based on informed, rational drug design principles versus high-risk screening strategies, the company has streamlined its drug discovery process to deliver product candidates to the clinic in less than 5 years from invention/patent priority dates.